Algert Global LLC Has $3.95 Million Stake in Arvinas, Inc. (NASDAQ:ARVN)

Algert Global LLC lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN) by 22.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 205,988 shares of the company’s stock after acquiring an additional 37,927 shares during the period. Algert Global LLC owned 0.30% of Arvinas worth $3,949,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Affinity Asset Advisors LLC boosted its position in shares of Arvinas by 180.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 630,000 shares of the company’s stock worth $12,077,000 after purchasing an additional 405,000 shares in the last quarter. Edmond DE Rothschild Holding S.A. bought a new position in Arvinas in the fourth quarter worth approximately $1,534,000. Kennedy Capital Management LLC grew its stake in Arvinas by 42.0% in the fourth quarter. Kennedy Capital Management LLC now owns 208,992 shares of the company’s stock valued at $4,006,000 after acquiring an additional 61,802 shares during the period. BIT Capital GmbH increased its holdings in shares of Arvinas by 291.7% during the fourth quarter. BIT Capital GmbH now owns 263,527 shares of the company’s stock valued at $5,052,000 after acquiring an additional 196,246 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Arvinas during the fourth quarter worth approximately $23,845,000. 95.19% of the stock is owned by institutional investors.

Arvinas Price Performance

NASDAQ:ARVN opened at $6.95 on Wednesday. The company has a market capitalization of $507.29 million, a P/E ratio of -2.51 and a beta of 2.21. The business has a fifty day simple moving average of $9.26 and a two-hundred day simple moving average of $17.16. Arvinas, Inc. has a 1 year low of $5.94 and a 1 year high of $37.38.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The company’s revenue was up 646.2% on a year-over-year basis. During the same period last year, the company posted ($0.97) earnings per share. As a group, analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Insider Activity

In other Arvinas news, insider Noah Berkowitz sold 8,658 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the sale, the insider now owns 110,023 shares in the company, valued at $945,097.57. This represents a 7.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock valued at $769,402 over the last quarter. Company insiders own 5.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ARVN shares. Oppenheimer downgraded shares of Arvinas from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 11th. Citigroup cut their price target on Arvinas from $10.00 to $9.50 and set a “neutral” rating for the company in a research note on Monday. Guggenheim lowered their price objective on Arvinas from $32.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Finally, Wells Fargo & Company dropped their price objective on Arvinas from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.97.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.